Navigation Links
Aegera Therapeutics welcomes two experienced executives to its board of directors
Date:4/24/2008

MONTREAL, April 24 /PRNewswire/ - Aegera Therapeutics Inc. is very pleased to announce the appointment of two experienced biotechnology and financial executives to its Board of Directors: Mr. Jeremy Curnock Cook, Executive Chairman and Founder of BioScience Managers Limited, and Mr. Gary Littlejohn, Managing Director of Desjardins Securities.

"Gary and Jeremy's extensive industry experience and networks will be critical for Aegera as we make key strategic decisions in support of the attainment of our corporate vision of becoming a profitable, public biotechnology company," commented Mr. James Rae, Chairman of the Board, Aegera Therapeutics Inc.

"I am extremely enthusiastic about joining Aegera's Board at such a critical and exciting time for the company," stated Mr. Curnock Cook. "Their recent clinical and business milestone achievements are very impressive by any measure and I look forward to working with management and the Board to assist the company in accelerating their efforts to achieve their very aggressive business plan."

"Aegera is one of Canada's premier biotechnology companies." added Mr. Littlejohn. "I look forward to working with the accomplished executive team to capitalize on their successes and to continue to build shareholder value both as a private and potentially as a public company."

Mr. Curnock Cook and Mr. Littlejohn join Aegera's existing Board consisting of the following members:

- Mr. James M. Rae, Chairman, President, Remedis Consulting

- Dr. Michael J. Berendt, President & CEO, Aegera Therapeutics

- Dr. Ines Holzbaur, Vice-President, GeneChem Management

- Mr. Serge Langford, Managing Partner, Multiple Capital

- Dr. Luc Marengere, Managing General Partner, Vengrowth Capital

Management

- Mr. Joseph Regan, B.Sc., MBA, Vice President, GrowthWorks Capital

- Mr. Lennie Ryer, B. Comm, CA, CFE, CFO and VP Finance, ConjuChem

The detailed biographies of Mr. Curnock Cook, Mr. Littlejohn and all of Aegera's Board Members can be viewed at http://www.aegera.com

About Aegera Therapeutics Inc.

Aegera Therapeutics is a well funded, clinical stage biotechnology company focused on developing drugs that control apoptosis to address major unmet medical needs. In addition to AEG33773, a compound in Phase 1 clinical development for the treatment of pain associated with diabetic neuropathy, Aegera has three programs in clinical development for oncology indications. Details of our programs can be viewed on our Website at http://www.aegera.com.


'/>"/>
SOURCE AEGERA THERAPEUTICS INC.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Aegera initiates Phase 1 clinical trial of AEG33773 - A small molecule in development for diabetic neuropathic pain
2. Human Genome Sciences and Aegera Therapeutics Announce Licensing and Collaboration Agreement on Novel Anti-Cancer Drugs
3. CardioVascular BioTherapeutics, Inc. Funding Wound Healing Trial with R&D Partnership
4. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
5. United Therapeutics to Announce First Quarter 2008 Financial Results Before Market Open on Thursday, May 1, 2008
6. ImaRx Therapeutics Satisfies Abbott Note Obligation Associated With the Acquisition of Urokinase
7. Sirion Therapeutics Preclinical Studies: Two New Potential Advances in Treatment of Retinal Diseases to be Presented at ARVO
8. CardioVascular BioTherapeutics, Inc. Announces Update on Timing of Form 10-K Filing
9. Cell Therapeutics, Inc. Announces Receipt of Letter From the NASDAQ Stock Market Regarding Non-Compliance With the Minimum Bid Price Requirement
10. BioSpace and IBC Life Sciences Announce Career Fair Alliance For Drug Discovery & Development of Innovative Therapeutics World Congress
11. Lorus Therapeutics presents new findings for the anticancer drugs LOR-253 and LOR-2040
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... -- VMS BioMarketing, a leading provider of patient support solutions, has ... (CNE) network, which will launch this week. The VMS CNEs ... professionals to enhance the patient care experience by delivering peer-to-peer ... care professionals to help women who have been diagnosed and ... ...
(Date:10/10/2017)... SAN DIEGO, CALIF. (PRWEB) , ... October 10, 2017 , ... ... website as part of its corporate rebranding initiative announced today. The bold new ... broaden its reach, as the company moves into a significant growth period. , It ...
(Date:10/10/2017)... 10, 2017 SomaGenics announced the receipt of ... develop RealSeq®-SC (Single Cell), expected to be the first ... (including microRNAs) from single cells using NGS methods. The ... to accelerate development of approaches to analyze the heterogeneity ... "New techniques for measuring levels of mRNAs in individual ...
(Date:10/9/2017)... (PRWEB) , ... October 09, 2017 , ... At its ... Dr. Christopher Stubbs, a professor in Harvard University’s Departments of Physics and Astronomy, has ... was a member of the winning team for the 2015 Breakthrough Prize in Fundamental ...
Breaking Biology Technology:
(Date:4/24/2017)... 24, 2017 Janice Kephart , ... Identity Strategy Partners, LLP (IdSP) , today issues ... President Trump,s March 6, 2017 Executive Order: ... vetting can be instilled with greater confidence, enabling ... all refugee applications are suspended by until at ...
(Date:4/17/2017)... , April 17, 2017 NXT-ID, Inc. ... company, announces the filing of its 2016 Annual Report on Form ... Exchange Commission. ... Form 10-K is available in the Investor Relations section of the ... on the SEC,s website at http://www.sec.gov . 2016 ...
(Date:4/11/2017)... April 11, 2017 Crossmatch®, a globally-recognized ... solutions, today announced that it has been awarded ... Projects Activity (IARPA) to develop next-generation Presentation Attack ... "Innovation has been a driving force within ... will allow us to innovate and develop new ...
Breaking Biology News(10 mins):